All viruses, irrespective of the disease they cause, have to replicate in order to survive. Drugs that block viral RNA or DNA replication by mimicking the natural building blocks of RNA and DNA (A, C, G, T/U) are known as nucleoside analogues. There are three distinct features of nucleosides that make them the preferred treatment for an infectious disease where a nucleoside is available: high barrier to resistance,broad spectrum of activity and high efficacy. This can be observed in the treatments of HSV (Aciclovir and Ganciclovir), HIV (Tenofovir, Zidovudine, Abacavir Emtricitabine and Lamivudine), HBV (Entecavir, Tenofovi, Adefovir, Lamivudine and Telbivudine) and HCV (Sofosbuvir).
Your PhD project will involve the design and chemical synthesis of a new class of nucleoside analogue, focusing on mimetic modifications to the ribose ring. You will also be involved in applying the mimetic nucleoside within the synthesis of current anti-viral drugs. You will receive training in organic synthesis, carbohydrate chemistry and medicinal chemistry. Transferable skills such as reporting of results orally and in writing, time management, project planning and management will be also developed.
Please quote FNS GS 2017-24 on your application.
Funding support is provided as follows;
100% UK/EU tuition fees for 3 years. Stipend support at Research Council rates for three years commencing academic year 2018/19. Current RCUK stipend: £14,553 per annum.
Source of Funding: Riboscience LLC and Keele University Faculty of Natural Sciences
Qualifications: Applicants should have or expect at least a good 2:1 honours degree (or an equivalent degree) in Chemistry. Any experience in synthetic organic or carbohydrate chemistry is a plus.
Contact for further information: For further information on the group: www.millertime.co.uk and @millerlabkeele For informal inquiries please contact Dr Gavin J Miller at firstname.lastname@example.org and include a CV